BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Pfizer

Getting FDA authorization for a COVID-19 vaccine may be just the first hurdle of many.

Coronavirus Vaccine Stocks: Challenges With Manufacturing, Distribution, And the Cold Chain

Tesla

CureVac B.V

Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.

3 Best Biotech Stocks to Buy Right Now

How seismic was the stock-market move that kicked off the week following news of an effective coronavirus vaccine candidate? It was the best week ever for inflows, according to BofA Global Research

The Tell: Pfizer vaccine news sparks $44.5 billion flood into the stock market—its biggest weekly inflow ever, says BofA

The biggest catalyst for global equities: COVID-19 vaccine.

Global stock funds see record inflows on Pfizer's COVID-19 vaccine

BioNTech and Pfizer Inc.'s unexpectedly efficacious COVID-19 vaccine candidate caught Wall Street and the medical community by surprise this week, yet the same experts who are thrilled by the news caution that the effectiveness of the vaccine will likely be lower in the real world.

BioNTech and Pfizer's COVID-19 vaccine is surprisingly effective, though experts question what effectiveness will look like in the real world

Carnival

SunPower

After the volatility of 2020, analysts see some calm in the offing. Here are 5 companies to invest in on those prospects.

5 Companies to Invest in for 2021 as Markets Price in Economy's Prospects

The BioNTech/Pfizer team has announced a 90% plus effective COVID-19 vaccine on 9 November 2020. They are probably going to submit a FDA EUA application in the 3rd week of November 2020 and will soon follow that up with a full FDA approval application.

BioNTech SE: Spectacular Success Still Extremely Undervalued

Why BioNTech Stock Slumped Today

Here's why The Lancet's editor-in-chief thinks an mRNA vaccine to prevent COVID-19 could be groundbreaking.

What Investors Need To Know About Pfizer's Potential Coronavirus Vaccine

The Pfizer-BioNTech coronavirus vaccine could protect patients from the virus for a year, BioNTech CEO Ugur Sahin told "Mornings with Maria" on Thursday.

Pfizer coronavirus vaccine expected to protect patients for a year: BioNTech founder

BioNTech SE (BNTX) CEO Ugur Sahin on Q3 2020 Results - Earnings Call Transcript

Pfizer developed its coronavirus vaccine in partnership with BioNTech. CNBC takes a look at the company's history.

What you need to know about BioNTech, the European company behind Pfizer's Covid-19 vaccine

Pfizer and BioNTech reached a supply deal Wednesday with the European Union for up to 300 million doses of their coronavirus vaccine. The EU will initially buy 200 million doses.

Pfizer, BioNTech Ink EU Deal For 300 Million Coronavirus Vaccine Doses

After reporting stellar efficacy results for their vaccine candidate earlier this week, Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) announced a supply deal with the European Commission. What Happened: The U.S. pharma giant and its German partner said have reached an agreement with the European Commission to supply 200 million doses of their investigational mRNA vaccine, codenamed BNT162b2, against SARS-CoV-2.

Pfizer-BioNTech Seals 200M Dose Vaccine Supply Deal With European Commission

AstraZeneca

Gilead Sciences

Eli Lilly

Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.

Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success

Pfizer Inc. and BioNTech SE announced Wednesday a deal to provide a supply of 200 million doses of its COVID-19 vaccine candidate to the European Union, marking the largest order for the potential vaccine to date. As part of the deal, the EU has an option to request an additional 100 million doses.

Pfizer, BioNTech reach deal to supply EU with 200 million doses of its COVID-19 vaccine candidate

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for the European Commission to request an additional 100 million doses. Deliveries are anticipated to start by the end of 2020, subject to clinical success and r

Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2

Inovio Pharmaceuticals

Johnson & Johnson

Investors are setting themselves up for disappointment.

5 Reasons Chasing COVID-19 Vaccine Stocks Is a Bad Idea

Causeway Capital Commentary- Update on Covid019 Vaccines: A Major Breakthrough for mRNA Technology

Nearly four months ago I wrote that should the Covid-19 vaccine being developed by Pfizer Inc. (NYSE:PFE) prove successful, it could generate revenue of $15 billion. That expectation is moving closer to reality after the New York-based pharmaceutical leader and partner BioNTech SE (NASDAQ:BNTX) announced on Monday their leading candidate worked 90% of the time.

Sales of Pfizer's Covid Vaccine Could Hit $4.6 Billion in 2021

Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis

Pfizer and BioNTech could make $13bn from coronavirus vaccine

Co-founded by Turkish scientists Uğur Şahin and his wife Özlem Türeci, BioNTech is now worth $25 billion.

Everything you need to know about BioNTech and the married couple behind the COVID-19 vaccine at the front of a global race

The German biotech thinks that its prospects are brighter than ever.

No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program

BioNTech on Tuesday signalled that order size would impact the per-dose price for its potential COVID-19 vaccine in the developed world.

BioNTech says vaccine pricing benchmark is for similar volumes

BioNTech (BNTX) miss estimates for earnings in the third quarter of 2020 while revenues beat the same.

News for BioNTech SE Stock (BNTX)